Druckenmiller makes a cancer stock his top buy

Billionaire investor Stanley Druckenmiller has made a cancer-focused stock one of his highest-conviction purchases.
That kind of positioning gets attention because Druckenmiller is known for concentrating capital when he sees asymmetric upside.
The thesis appears tied to the potential value of a developing oncology pipeline rather than short-term momentum alone.
For biotech investors, the key question is whether upcoming clinical data can justify the conviction behind the position.